John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...
Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback